Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22887047 | 1.00 | HSD11B1 (0.35) | HSD11B1 | |
| SCHEMBL20727450 | 1.00 | HSD11B1 (0.35) | HSD11B1 | |
| SCHEMBL12108434 | 0.86 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL12045776 | 0.79 | CYP2C9 (0.36) | HSD11B1 | |
| SCHEMBL22347211 | 0.79 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL22347210 | 0.79 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL25450425 | 0.77 | — | — | |
| SCHEMBL26152318 | 0.76 | HSD11B1 (0.36) | HSD11B1 | |
| SCHEMBL25011378 | 0.76 | CYP2C9 (0.34) | — | |
| SCHEMBL8384552 | 0.76 | CYP1A2 (0.40) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-28 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022150446-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022135567-A1 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2021260090-A1 | CYCLOBUTYL-UREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-30 | — | — | WO | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | HSD11B1 1727/4885 |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | KCNA4, KCNMB4, KCNA7 | HSD11B1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.